Zeo ScientifiX, Inc.
Moat Score — Zeo ScientifiX, Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Zeo ScientifiX holds three issued U.S. patents covering its nanoparticle and PPX technologies, plus IND/emergency IND approvals for Zofin-related protocols -- real but narrow IP in a field where most rivals sell similar tissue-derived products without comparable protection. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | The company reports an unusually high ~83% gross margin on cash-pay biologic sales, but this reflects the direct-to-provider sales model common across the whole crowded birth-tissue-biologics category, not a company-specific cost edge over named rivals like Kimera Labs or MiMediX. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With more than a dozen named competitors (Kimera Labs, Frontier Biologics, Benev, Regenexx, etc.) selling similar allogeneic and autologous products to the same provider base, Zeo ScientifiX has limited ability to set prices independent of the broader crowded market. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Biologics sales to individual providers generate no network effect; each provider relationship is independent and additional customers do not increase the value of existing ones. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Providers who have validated Zofin or PPX protocols in their clinical workflow face some switching friction, but with over a dozen similar allogeneic/autologous products on the market, switching costs are modest rather than structural. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | At roughly $5.2 million in FY2025 revenue and a $1.5 million asset base, Zeo ScientifiX is far too small to occupy an efficient-scale niche that deters the many similarly small named competitors from entering or persisting. |